Johnson & Johnson announces positive results from phase 3 MajesTEC-9 study of Tecvayli in patients with multiple myeloma: Raritan, New Jersey Friday, January 16, 2026, 10:00 Hrs [ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback